Meet SkylineDx
Quality of our life is in our genes
At SkylineDx, we live to make a difference. It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease.
Disease often harbors genomic changes in the cells. By measuring these genomic alterations, we can have a better understanding of how the disease will develop over time. With more information available on the course of the disease, care providers can set out a more personalized treatment path, offering the patient a better quality of life.
To facilitate our mission, we are continuously improving the world of gene signature-based (genomic) diagnostic testing. Our story is one of passion, innovation, and dedication. Founded with a vision to personalize healthcare through state-of-the-art diagnostics, we have cultivated a culture that thrives on collaboration, integrity, and relentless pursuit of excellence.
We THINK about how our innovations can impact many lives
Historically and generally, patients with the same type of disease are treated the same. Despite knowing that a group of patients will respond less or not respond at all. In oncology, inflammatory diseases, and many other indications, the large clinical unmet need is identifying upfront who will respond and who will not. Who will need surgical intervention and who does not. Knowing this prior to treatment saves debilitating side effects, additional hospitalizations, complications, medication and medical interventions, and, ultimately, a worse quality of life.
Luckily, recent decades have shown vast research interest in finding biomarkers that can classify a patient as responder versus non-responder, at high risk for developing metastasis versus at low risk or at high risk of having a specific disease or to rule out disease. These biomarkers have a pivotal role in addressing the clinical unmet need.
At SkylineDx, it is our aim to translate this biomarker research into a tangible test (molecular assay) that fulfills all criteria for safe use in the clinic. Ultimately, it supports care providers and patients in decision-making on whether a therapy will work or surgery is necessitated.
See how we have rocketed to new heights
Scroll to see more ›
Our mission and vision
At SkylineDx, we live to make a difference.
It is our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease.
We aspire to provide better diagnostic tools for care providers, to enhance the quality of every patient’s life.
Looking ahead, our vision is bold and ambitious. We envision a future where every patient receives individualized medical care, based on the genomic profile of their disease.
At the heart of SkylineDx is a culture defined by four pillars:
Live. Think. Battle. Care.
We LIVE to make a difference, fueling our passion to drive positive change in healthcare
We THINK about how our innovations can impact many lives, constantly seeking new ways to push the boundaries of what’s possible
We BATTLE to make progress in a conservative world, challenging norms and overcoming obstacles with determination and resilience
We CARE about the people we serve, approaching our work with empathy, compassion, and a deep sense of responsibility
At SkylineDx, our identity is defined by our unwavering commitment to our core values. These values serve as the compass guiding our every decision and action, ensuring that we stay true to our mission. Together, these values form the foundation of our culture and guide us as we navigate the landscape of healthcare. With our brand visor as our compass, we are driven by a shared purpose: to make a meaningful difference in the world by delivering science-based solutions that improve lives.
For us it's personal
SkylineDx Team
At SkylineDx, we’re on a mission to revolutionize healthcare. Our dedicated team of experts is laser-focused on discovering novel gene-based biomarkers and transforming them into registered diagnostics that are ready to change clinical practice. The status quo is not all we can achieve– we’re pushing boundaries, breaking barriers, and paving the way for a new era of personalized medicine.
Corporate Impact
It’s not all about work. We believe in giving back to the communities we serve, focusing on health and wellbeing: from cleaning beaches to running marathons for World Cancer Day. At SkylineDx, we actively participate in social events organized by and for colleagues. Additionally, we have periodical educational sessions to increase mental health and skin cancer awareness. And we volunteer for various local initiatives. We take our corporate social responsibility seriously. If you have an initiative that would be interesting for our team, please don’t hesitate to reach out.
Our trusted collaborations
What others have to say about us
Latest News
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 25, 2024—SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the...
The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making. ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October 13,...
The Merlin Test (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), October...
ROTTERDAM, (the Netherlands), SAN DIEGO (CA, USA), October 8, 2024 – SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announces...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), July 9, 2024: — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, proudly...
ROTTERDAM (the Netherlands), SAN DIEGO (CA, USA), May 30, 2024: — SkylineDx announces the presentation of groundbreaking data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Dr. Teresa Amaral,...
SkylineDx is ISO 13485:2016 certified